T. Rowe Price Forms Exclusive Partnership with UBS Global Wealth Management to Offer Asian HNWIs Access to Flagship Health Sciences Equity Strategy
T. Rowe Price today announced its first exclusive distribution partnership with UBS Global Wealth Management in Singapore and Hong Kong to offer the T. Rowe Price Health Sciences Equity Strategy (the “Strategy”). Under the partnership, the Strategy will be available exclusively through UBS to private wealth clients in these markets, allowing them timely access to T. Rowe Price’s investment expertise in the health science sector as the pandemic accelerates innovations and breakthroughs.
The Strategy is one of the most established strategies dedicated to investing in health sciences companies with US$19.3 billion asset under management1 and a long track record dating back to its inception in 1995.
Dr. Ziad Bakri, portfolio manager of the Strategy, commented, “The diverse and dynamic health sciences sector is amid a transformative period of innovation, creating significant investment opportunities across a broad array of companies in healthcare, pharmaceuticals and life sciences. We focus on identifying innovative companies that are developing game-changing medical therapies, as well as those offering quality and cost-effective health care services that can lead to long-term value creation for investors. A distinct focus of the Strategy is companies which develop therapeutics for diseases that affect large patient populations and need improved treatment options, such as cancer, diabetes, and Alzheimer’s.”
Based in the firm’s headquarter in Baltimore, U.S., Bakri is supported by an in-house research team with diverse and extensive medical and scientific background, including several Ph.Ds. Bakri’s investment expertise is grounded in 16 years of research and analysis on key trends in the healthcare and biotech sectors. He also has years of experience as a medical practitioner and emergency medicine residency prior to moving into investments.
Elsie Chan, Head of Distribution for Asia ex-Japan at T. Rowe Price, commented, “We are pleased to offer this innovative Strategy through our partnership with UBS Global Wealth Management to meet sophisticated investors’ demand for an investment solution to capture appealing growth prospects brought by secular trends, such as the shift from medical treatment to prevention, immunotherapy and the prolonging of life through new technology. This partnership demonstrates our commitment to deliver market-leading and differentiated investment solutions to investors in Asia.”
Jansen Phee, Head of Fund Investment Solutions APAC at UBS Global Wealth Management, commented, “Health Care is a key investment theme which offers diverse opportunities ranging from defensive compounders in the pharmaceutical area to emerging high growth companies involved in genetic therapies and health technology. The current environment further highlights the significance of Health Care as an important long-term theme. UBS is pleased and committed to working with T. Rowe Price to offer unique solutions in APAC. T. Rowe Price’s Health Care solution has been an established offering for many years in the US with a great track record. This launch underlines UBS’ ability to leverage scale and extensive partnerships to deliver exclusive solutions to our clients, and further cements our leadership position in providing differentiated investment opportunities.”
Latest News